• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Alexion, Cincinnati Children’s launch rare disease innovation fund

Alexion, Cincinnati Children’s launch rare disease innovation fund

October 15, 2014
CenterWatch Staff

Alexion Pharmaceuticals, a Cambridge, Mass.-based developer of breakthrough therapies for patients with severe and life-threatening rare diseases, and Cincinnati Children’s Hospital Medical Center have established the Alexion Rare Disease Innovation Fund for the advancement of research in rare disease.

“Collaborations between industry and academia are important to drive innovation for patients suffering from rare diseases and we look forward to working with Cincinnati Children’s to advance our research programs, which are focused on developing life-transforming therapies for patients with devastating disorders,” said Martin Mackay, Ph.D., executive vice president and global head of R&D at Alexion.

Alexion will have the opportunity to fund selected research programs through the Alexion Rare Disease Innovation Fund.  Following completion of the funded research programs, Alexion will have an exclusive option to enter into a licensing agreement for these programs.

The Alexion fund is a focused opportunity within Cincinnati Children’s broader Innovation Fund, which covers all therapeutic areas and technology types. Alexion will focus its selections based on the company’s specialty of developing new treatments for complex and rare diseases.

The company decided to collaborate with Cincinnati Children’s because of the medical center’s strength in rare- and complex-disease research. Research programs selected for the Alexion fund will receive funding commensurate with project development needs and based on projects reaching specific milestones.

Upon entering into any subsequent licensing agreement, Cincinnati Children’s will be eligible to receive certain development and commercial milestone payments, as well as royalties on product sales from Alexion. Alexion will have the primary responsibility for further clinical development and commercialization of products arising from the collaboration. The collaboration and Innovation Fund are managed by Cincinnati Children’s Center for Technology Commercialization.

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Virtual Doctoer

    Simple Changes Can Make Trials More Patient Friendly

  • Drug approval

    Two-Thirds of Trial Subjects for Drug Approvals Are Outside the U.S.

  • VaccinewithNeedle-360x240.png

    Rules of Vaccine Approval May Be Changing, But Statistical Analysis Tools Remain Constant

  • AskTheExperts-360x240.png

    Ask the Experts: Trial Operations Adjustments in a Remote World

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing